Creo Medical Group (FRA:1RC) ROCE %: -114.76% (As of Dec. 2025)

What is Creo Medical Group ROCE %?

Creo Medical Group FRA:1RC 53 ROCE % is -114.76% as of Dec. 2025. GuruFocus rates FRA:1RC with a GF Score™ of 53/100 and a GF Value™ of €0.18. The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Creo Medical Group's annualized ROCE % for the quarter that ended in Dec. 2025 was -114.76%.

Creo Medical Group (FRA:1RC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Creo Medical Group ROCE % Related Terms

Creo Medical Group ROCE % Historical Data

* Premium members only.

The historical data trend for Creo Medical Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Creo Medical Group ROCE % Chart

Creo Medical Group Annual Data

Trend

Feb15

Feb16

Jun17

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-39.77

-43.54

-42.27

-52.66

-34.82

Creo Medical Group Semi-Annual Data
	Feb15	Feb16	Dec16	Jun17	Dec17	Jun18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
ROCE %	Get a 7-Day Free Trial															-36.44	-47.07	-54.16	59.74	-114.76

53GF Score

Creo Medical Group PLC FRA:1RC

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Creo Medical Group ROCE % Calculation

Creo Medical Group's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-19.664	/	( ( (78.477 - 24.75)	+	(67.565 - 8.346) )	/ 2 )
	=	-19.664	/	( (53.727	+	59.219)	/ 2 )
	=	-19.664	/	56.473
	=	-34.82 %

Creo Medical Group's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	-76.368	/	( ( (80.936 - 7.058)	+	(67.565 - 8.346) )	/ 2 )
	=	-76.368	/	( ( 73.878	+	59.219 )	/ 2 )
	=	-76.368	/	66.5485
	=	-114.76 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -114.76% mean?

Creo Medical Group (FRA:1RC) has a ROCE % of -114.76% as of Dec. 2025.

Is Creo Medical Group's ROCE % too high?

Creo Medical Group's current ROCE % is -114.76%. Overall, Creo Medical Group has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.

How does Creo Medical Group's ROCE % compare to ABT and SYK?

Creo Medical Group's ROCE % of -114.76% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creo Medical Group's current ROCE % is -114.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Creo Medical Group stock overvalued right now?

Creo Medical Group (FRA:1RC) has a current ROCE % of -114.76%. The stock's GF Value™ is €0.18, compared to a current price of €0.15 — trading 18.9% below its estimated fair value. The current ROCE % is -114.76%. Creo Medical Group's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Creo Medical Group (FRA:1RC), the current ROCE % is -114.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Creo Medical Group (FRA:1RC) Overvalued in 2026?

Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued. The current stock price of €0.15 is trading 18.9% below its estimated GF Value™ of €0.18.

Key valuation signals for FRA:1RC:

ROCE %: -114.76%
GF Value™: €0.18 vs. price of €0.15 (18.9% below fair value)
GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the FRA:1RC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Creo Medical Group Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies LSE:AOTI LSE:IHC LSE:RUA LSE:EKF LSE:SUN LSE:NIOX ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA STE ZBH XSWX:SOON SHSE:688271

Other Exchanges CREO:UK

Address Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH

Website https://www.creomedical.com

Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.

53GF Score

Get the complete analysis for FRA:1RC

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15

Price

€0.18

GF Value

View FRA:1RC Analysis

See ROCE % data for all stocks →